NewSquare Capital LLC Has $4.26 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

NewSquare Capital LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,336 shares of the biopharmaceutical company’s stock after buying an additional 1,247 shares during the quarter. NewSquare Capital LLC’s holdings in Gilead Sciences were worth $4,264,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Nilsine Partners LLC boosted its stake in shares of Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. boosted its stake in shares of Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares in the last quarter. Financial Counselors Inc. boosted its stake in shares of Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 130 shares in the last quarter. Finally, Institutional & Family Asset Management LLC boosted its stake in shares of Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 140 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares in the company, valued at approximately $7,386,496.48. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Barclays decreased their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. UBS Group cut their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Finally, Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $84.57.

Gilead Sciences Price Performance

Shares of GILD traded down $0.18 during midday trading on Wednesday, reaching $66.85. The stock had a trading volume of 3,916,870 shares, compared to its average volume of 7,258,320. The company has a market capitalization of $83.23 billion, a price-to-earnings ratio of 14.89, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. Gilead Sciences, Inc. has a 12-month low of $65.90 and a 12-month high of $87.86. The company’s 50-day moving average is $71.68 and its 200 day moving average is $76.46. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.67 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post 6.28 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.61%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.